Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1][1]. Group 1: Legal Action and Allegations - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and has set a deadline of March 16, 2026, for investors to seek the role of lead plaintiff in the class action [1]. - The complaint alleges that Vistagen and its executives violated federal securities laws by making false assertions about the likelihood of success for fasedienol based on prior clinical trial results, which misled investors [1][1]. - The lawsuit follows the announcement on December 17, 2025, that the PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint, resulting in an over 81% drop in the stock price to $0.88 per share [1][1]. Group 2: Investor Information - Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its capability in handling such cases [1].

Core Viewpoint - A class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging securities fraud related to misleading statements about the FDA's feedback on the company's drug relacorilant [1]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between October 31, 2024, and December 30, 2025 [1]. - The complaint claims that Corcept Therapeutics made false statements regarding their interactions with the FDA and the approval prospects of the relacorilant NDA [1]. - The FDA had expressed concerns about the adequacy of the program assessing relacorilant's effectiveness, which was not disclosed by the company [1]. Group 2: Investor Information - Investors who suffered losses during the relevant timeframe have until April 21, 2026, to request appointment as lead plaintiff [1]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [1]. - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [1].

Core Viewpoint - Moleculin Biotech, Inc. is advancing its pivotal MIRACLE Study evaluating Annamycin in combination with cytarabine for patients with relapsed or refractory Acute Myeloid Leukemia, with promising results expected from the ongoing clinical trial [3][6]. Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses [5]. - The lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity associated with current treatments [5]. Clinical Development - The MIRACLE Study (MB-108) is an adaptive Phase 3 trial designed with FDA input, involving an initial cohort of 45 patients [3][6]. - The study aims to evaluate the safety and efficacy of Annamycin in combination with cytarabine, with an interim unblinding planned after the initial cohort's treatment completion [3][6]. - The trial builds on positive outcomes from the earlier MB-106 Study, where Annamycin showed overall survival rates exceeding historical benchmarks in a challenging patient population [3]. Additional Pipeline - The company is also developing WP1066, an Immune/Transcription Modulator targeting various cancers, and WP1122, an antimetabolite for potential treatment of pathogenic viruses and certain cancer indications [7].

Core Viewpoint - Agios Pharmaceuticals, Inc. is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 trial of Mitapivat in Sickle Cell Disease, which led to a significant drop in stock price [1]. Group 1: Trial Results - On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial, which met one primary endpoint but failed to achieve a statistically significant improvement in the annualized rate of pain crises [1]. - The key secondary endpoint, change from baseline in PROMIS Fatigue, was also not met during the trial [1]. Group 2: Stock Market Reaction - Following the trial results, Agios' stock price fell by $22.33 per share, opening at $23.16 per share [1].

Core Insights - Indivior Pharmaceuticals announced findings from a study indicating that adherence to SUBLOCADE is linked to significantly lower healthcare utilization and costs for patients with opioid use disorder (OUD) compared to other medications and nonadherent patients [1][5][8] Group 1: Study Findings - The study published in Frontiers in Public Health shows that patients adhering to SUBLOCADE had 42% lower adjusted non-MOUD medical costs, amounting to $15,017 less annually per patient compared to those adhering to other forms of MOUD [8][9] - Patients on SUBLOCADE experienced the lowest rates of inpatient admissions, emergency department visits, and detoxification services, highlighting the treatment's effectiveness in reducing acute healthcare needs [4][8] - The study reinforces the importance of evaluating OUD treatment based on total healthcare costs, suggesting that long-acting therapies like SUBLOCADE can lead to system-wide savings while improving patient care continuity [6][9] Group 2: Treatment Context - SUBLOCADE is indicated for the treatment of moderate to severe OUD and should be part of a comprehensive treatment plan that includes counseling and psychosocial support [10] - The study's findings contribute to the growing evidence that long-acting injectable buprenorphine treatments support sustained engagement in care and reduce costly acute healthcare use [2][5] - Indivior is positioned as a leader in long-acting injectable treatments for OUD, focusing on evidence-based treatment and advancing the understanding of OUD as a chronic but treatable condition [22]

Core Viewpoint - The FDA has granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome, highlighting the urgent unmet medical need for patients with this rare genetic skin disorder [1][2]. Company Overview - Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [7]. - The company aims to address unmet medical needs for patients and their families, with a pipeline that includes products targeting various rare conditions [7]. Product Development - QRX003 lotion (4%) is currently being evaluated in two late-stage whole-body clinical trials to assess its safety and efficacy for treating Netherton Syndrome [3]. - The product has previously received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency, which provides benefits such as market exclusivity upon approval and tax credits for clinical testing [4]. Regulatory Designations - In addition to Fast Track Designation, QRX003 has also been granted Pediatric Rare Disease Designation by the FDA, indicating its significance in treating pediatric patients with this condition [4]. - The Fast Track program allows for more frequent communication with the FDA and the potential for accelerated regulatory review pathways [6]. Disease Background - Netherton Syndrome is a rare inherited skin disorder caused by mutations in the SPINK5 gene, leading to severe skin barrier dysfunction and chronic inflammation [5]. - There are currently no FDA-approved therapies for Netherton Syndrome, and treatment options are limited to supportive care and off-label therapies [5].

Core Viewpoint - NanoViricides is advancing its lead clinical stage drug NV-387, an oral broad-spectrum antiviral, with the completion of its Phase II clinical product manufacturing and plans to present at the NIBA's 152nd Investment Conference [1] Company Overview - NanoViricides, Inc. is a clinical stage company focused on developing innovative antiviral drugs that cannot be evaded by viruses [1] - The company’s lead drug candidate, NV-387, targets multiple viral infections including RSV, Influenza, Coronaviruses, Monkeypox, Smallpox, and Measles [1] Clinical Development - The manufacture of NV-387 Oral Gummies for clinical trials is complete, with dosing expected to start once site readiness is confirmed [1] - NV-387 has successfully completed a Phase I clinical trial with healthy human subjects, showing no dropouts or adverse events, indicating excellent safety and tolerability [1] - The drug has been approved to enter a Phase II clinical trial for the treatment of Monkeypox by the regulatory agency ACOREP in the Democratic Republic of Congo [1] Technology and Mechanism - NanoViricides employs a novel mechanism of action termed "Re-Infection Inhibition," allowing for broad-spectrum antiviral activity [1] - The nanoviricide platform mimics host cells, presenting virus-binding ligands that enable it to engulf and neutralize virus particles [1] - This technology is designed to prevent viruses from escaping treatment, even as they undergo genetic changes [1] Upcoming Events - Anil R. Diwan, PhD, President and Executive Chairman, will present at the NIBA conference on March 12, 2026, and will be available for one-on-one investor meetings [1]

Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing drugs for pancreatic cancer and other fibrotic cancers, utilizing Focal Adhesion Kinase (FAK) inhibitors as a key target in their research [5][6]. Recent Developments - CEO Dr. Chris Burns will present at the Life Sciences Investor Forum on March 12th (US time) / March 13th (AU time), 2026, providing an opportunity for real-time interaction with investors [1][2]. - The company is currently conducting the ACCENT trial for its drug Narmafotinib (AMP945), which has achieved a confirmed response rate of 42% and a median progression-free survival (mPFS) of 7.7 months in patients with advanced pancreatic cancer [6][7]. Clinical Trials - Narmafotinib is being tested in combination with gemcitabine and Abraxane in the ACCENT trial, which has surpassed the benchmark response rate of 23% from the MPACT study [6][7]. - A second trial, AMPLICITY, is underway, investigating the combination of Narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients, with sites opened in both Australia and the US [8]. Future Plans - The company has aligned with the FDA on the structure of a planned registrational Phase 2b/3 trial for Narmafotinib, indicating a strategic move towards further clinical validation and potential market entry [7].

Core Insights - The article discusses the potential market challenges ahead, emphasizing the importance of investing in safe Dividend Aristocrats amid rising geopolitical tensions and economic uncertainties [1][2] - It highlights the characteristics of Dividend Aristocrats, which are companies that have consistently increased dividends for at least 25 years, making them attractive for long-term investors seeking stability [1][2] Summary by Company Abbott Laboratories - Abbott Laboratories announced a 6.8% dividend increase in December, marking its 54th consecutive year of dividend growth, with a total increase of over 70% since 2020, currently yielding 2.10% [1] - The company operates in various segments, including Medical Devices, Nutritional Products, Diagnostic Products, and Established Pharmaceutical Products [1] Automatic Data Processing (ADP) - ADP is a leader in payroll and HR services, providing cloud-based solutions to over 80% of Fortune 100 companies, with a current dividend yield of 2.94% [1] - The company serves a diverse client base, offering a range of human capital management solutions, including payroll services and compliance services [1] Coca-Cola - Coca-Cola pays a reliable 2.50% dividend and has seen organic revenue growth of 5% in 2025, with expectations of 4% to 5% growth in 2026 [2] - The company offers over 500 brands and is the world's largest beverage company, with a significant market presence in sparkling beverages and ready-to-drink products [2] Johnson & Johnson - Johnson & Johnson, trading at 14.5 times forward earnings, offers a 2.07% dividend and is recognized for its diversified healthcare product portfolio [2] - The company operates in two main segments: MedTech and Innovative Medicine, focusing on various therapeutic areas [2] NextEra Energy - NextEra Energy raised its quarterly dividend by 10% and has committed to 10% annual dividend growth through this year, with a current yield of 2.44% [2] - The company operates through subsidiaries focused on electric power and energy infrastructure, including Florida Power & Light and NextEra Energy Resources [2]

Core Insights - Scienture Holdings, Inc. has formalized multiple Group Purchasing Organization (GPO) agreements for its naloxone product, REZENOPY, which is expected to penetrate approximately 60% of the U.S. institutional market [1][2] - The U.S. naloxone market is valued at approximately $141 million annually, with 9.4 million prescription units, presenting a significant commercial opportunity for REZENOPY [1][3] - REZENOPY is the highest-dose FDA-approved naloxone nasal spray, designed for emergency treatment of opioid overdoses, and is positioned to drive broader adoption and market share [2][3] Company Overview - Scienture Holdings, Inc. focuses on developing and commercializing specialty pharmaceutical products that address unmet market needs, enhancing value for patients, physicians, and caregivers [8] - The company operates through its wholly-owned subsidiary, Scienture, LLC, which is dedicated to bringing unique specialty products to market [8] Product Information - REZENOPY (naloxone HCl) Nasal Spray 10 mg is indicated for emergency treatment of known or suspected opioid overdose, intended for immediate administration in settings where opioids may be present [4][5] - The product is supplied as a carton containing two blister packages, each with a single spray device [4]